ADAPTIMMUNE’S PERFORMANCE. 3.1 ADAPTIMMUNE agrees that during the TERM of this SUB-LICENSE, any LICENSED T CELL PRODUCTS for use or sale by ADAPTIMMUNE or its AFFILIATES in the UNITED STATES will be manufactured substantially in the UNITED STATES. Upon request of ADAPTIMMUNE, LTC agrees to use commercially reasonable efforts to obtain the reasonable cooperation of the PARENT LICENSORS under the PARENT LICENSE to obtain a waiver of this requirement from the UNITED STATES government, and, in the event such waiver is obtained, LTC will be deemed to have waived the obligations of this Section 3.1.
Appears in 5 contracts
Samples: License Agreement (Adaptimmune Therapeutics PLC), Sub License Agreement (Adaptimmune Therapeutics PLC), Sub License Agreement (Adaptimmune Therapeutics PLC)